Our vision is to improve the treatment of severe diseases in order to provide benefits for both patients and society as a whole.

Oasmia in brief

Our vision is to improve the quality for treatment of severe diseases. Researching and developing next generation medicines, our focus is on advancing oncology treatments.


At Oasmia, we’re developing the next generation of drugs with focus on oncology.


At our EMA and FDA-approved production facility we manufacture drugs for both clinical trials and sales.

Our technology

Our nanoparticle platform XR17 possesses unique properties to improve current and future medicines.

The Share


Oasmia Pharmaceutical Announces Strategic Move to Bolster Efforts for its Veterinary Division

Company intend to move veterinary assets to United States; plans new FDA study
Read more

Oasmia Pharmaceutical Reports Positive Results from Study on Weekly Administration of Apealea® (Paclical®)

Results from a dose-finding study with weekly administration of Apealea (alternatively branded Paclical in some international regions) in patients with metastatic breast cancer are now available.
Read more

Oasmia Pharmaceutical AB’s Warrant Programs Fully Subscribed

Uppsala, Sweden, December 7, 2016 --- Oasmia Pharmaceutical (publ.) (”Oasmia” or ”The Company”) announces hereby that the previously announced warrant programs for the Oasmia management and Bo...
Read more
To news archive